National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "6. Assessing the Likely Utilization of New Vaccines." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
80
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Aggregation of Component Scores into an Overall Score

Research on how individuals formulate overall opinions on health protection measures indicates that the various components of the HBM differ in their degree of influence on final attitudes. Thus, the four component scores must be weighted according to their expected leverage on provider or lay behavior. The weights used in this analysis were as follows: risk (1); severity (2); benefits (2); barriers (−3). The negative sign for the barriers weight reflects the fact that a high score is less conducive to acceptance (Becker, 1974; Becker et al., 1977a,b,c).

Given these weights, both weighted additive and weighted multiplicative methods of combining scores are plausible. A weighted additive method would treat each factor as independent; a weighted multiplicative method might allow for the fact that two or more factors have an interactive effect on the overall likelihood of acceptance. The two methods considered for combining categories within the lay or provider domain were:


Weighted Additive Method

Weighted Multiplicative Method

As shown in Tables 6.2 and 6.3, the two methods give similar results, at least in terms of the ranking of the vaccines with respect to utilization. However, two theoretical considerations favor the multiplicative combination. First, the various HBM dimensions are actually subjective estimates or probabilities of some occurrence or outcome (e.g., the perceived likelihood of contracting a condition), and therefore the overall HBM estimate is appropriately the product of the individual-component probabilities. Second, it would not make conceptual sense to construct an HBM formula that would yield some predictive probability for a situation in which the estimate for any given component was zero (e.g., in the case of an individual who felt there was no possibility at all of contracting the condition). An additive model would still yield an overall HBM estimate by summing the values for the remaining model components; however, a multiplicative model would yield an overall estimate of zero. (The multiplicative approach is illustrated in Haefner and Kirscht, 1970.) Both methods have been carried forward to illustrate that they ultimately yield similar results.

Aggregation of Lay and Provider Weighted Scores

The additive and multiplicative combination of total lay and provider scores (from Tables 6.2 and 6.3) is shown in Table 6.4. Again, theoretical considerations favor the multiplicative score

Page
80
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)